Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: Implications for its use in cancer therapy

Int J Oncol
August 2016
https://www.ncbi.nlm.nih.gov/pubmed/27279602

Functional modulation on macrophage by low dose naltrexone (LDN)

Int Immunopharmacol
October 2016
https://www.ncbi.nlm.nih.gov/pubmed/27561742

The Uses of Low-Dose Naltrexone in Clinical Practice

BMJ Case Reports
January 2018
https://www.researchgate.net/publication/328997819_Issue_4_The_Uses_of_Low-Dose_Naltrexone_in_Clinical_Practice

Jarred Younger, PhD - The Ten Most Important Fibromyalgia Discoveries of 2016 and 2017 (2017 Conference) (LDN, low dose naltrexone)

People with rheumatological conditions are much more likely to have fibromyalgia than the general population, Lupus in particular was indicated to be the most likely rheumatological condition where fibromyalgia was also present. 

Anthony Turel, MD - Role of the Opioid System in Immune-Mediated Disease (2017 Conference) (LDN, low dose naltrexone)

Leonard Weinstock, MD - POTS and Mast Cell Activation Syndromes (2017 Conference) (LDN, low dose naltrexone)

Dr Leonard Weinstock is from St Louis in Missouri and helps patients with GI Issues and other autoimmune conditions.

Kent Holtorf, MD - Immune Dysfunction and Chronic Lyme Disease (2017 Conference) (LDN, low

Dr Kent Holtorf deals specifically with Lyme Disease in this presentation and its impact upon the immune system, explaining the process he uses to test for and diagnose Lyme. 

Martin Dayton, DO - LDN Case Studies (2016 Conference) (LDN, low dose naltrexone)

Dr Martin Dayton shares three case studies of patients suffering from follicular B-cell non Hodgkin's Lymphoma who were treated with nothing more than Low Dose Naltrexone (LDN).